EDUARDO
DÍAZ-RUBIO GARCÍA
Investigador fins a 2020
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario 12 de Octubre (25)
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
2019
-
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383
-
Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing
Scientific Reports, Vol. 9, Núm. 1
-
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
2018
2017
-
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome
PLoS ONE, Vol. 12, Núm. 11
2016
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
-
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2014
-
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data
The Lancet Oncology, Vol. 15, Núm. 4, pp. 406-414
-
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers
Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421
-
TTD consensus document on the diagnosis and management of exocrine pancreatic cancer
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878
2012
2011
-
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84
2009
-
Consensus on the treatment of pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 11, Núm. 5, pp. 290-301
2007
-
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer
Clinical Colorectal Cancer, Vol. 6, Núm. 7, pp. 522-528